{"entity":{"id":"nct06786026","kind":"trial","name":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC","aka":[],"tldr":"A phase 2 trial of bevacizumab, iparomlimab and tuvonralimab and nab-paclitaxel in triple-negative breast cancer, run by Fudan University, now recruiting.","summary":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC is a phase 2, interventional study registered as NCT06786026 by Fudan University, with a registry enrolment figure of 60 participants, started 2024-10-09 and due to reach its primary completion in 2025-09-30. Interventions recorded: bevacizumab; QL1706; Nab paclitaxel. Conditions listed: TNBC, Triple Negative Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06786026","url":"https://clinicaltrials.gov/study/NCT06786026"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["bevacizumab","iparomlimab-tuvonralimab","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06786026","phase":"2","setting":"QL1706 Plus Nab-paclitaxel +/- Bevacizumab As 1L Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: a Non-randomized, Multicenter Phase II Study","sponsor":"Fudan University","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06786026/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}